The Aeras Global TB Vaccine Foundation, which was founded to develop new, cost-effective TB vaccines for use in the developing world, has licensed a discovery of a protein that is able to 'wake up' dormant Mycobacterium tuberculosis bacteria that cause TB.
The research and the fundamental knowledge that came out of it could be used to develop a vaccine that either stops infecting TB bacteria from taking hold or, for the one in every three people world-wide who are already carrying a latent TB infection, prevents dormant bacteria from 'waking up'. Another possible strategy could be to deliberately 'wake up' dormant bacteria in a controlled way so they can be destroyed with antibiotics.
In the late 1990s, researchers funded by BBSRC discovered a new family of proteins that were able to resuscitate bacteria found harmlessly in and around the human body. When 'awoken' from dormancy the bacteria were then much more susceptible to attack from antibiotics. The team led by Professors Mike Young and Doug Kell at Aberystwyth University together with Prof Arseny Kaprelyants of the Bakh Institute of Biochemistry, Russian Academy of Sciences, Moscow, identified the gene in the bacterium that produced the protein and went on to discover the corresponding genes in M. tuberculosis. This research has now been licensed by Aeras after years of development. Aeras plans to take its recombinant BCG (AERAS-407) vaccine, based in part on the Aberystwyth work, to clinical trial in 2009.
Prof Young, now based in Aberystwyth University's newly formed Institute of Biological, Rural and Environmental Studies, said: "Current TB treatments can go on for over six months and can still leave bacteria in the body that can cause the disease when they resume active growth and multiplication. Our discovery, which is now being developed into a vaccine, might help prevent the establishment of persistent infections in the first place or, alternatively, it might prevent persisting organisms in individuals with latent TB from reawakening at all.
"TB kills around 1.7 million people around the world every year. I hope that our research will now be rapidly translated into a vaccine that can help as many of these people as possible."
Dr Alf Game, BBSRC Deputy Director of Research, said: "This discovery came out of research in the basic biology of a different bacterium. It shows that we need to strive to understand the fundamental workings of the world around us and from that we can identify how to tackle challenges, such as dangerous diseases, that we all face."
Press Office | alfa
Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)
CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy